Sevirumab clinical trials
How each study uses sevirumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Sandoz (2) · Johns Hopkins Bloomberg School of Public Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Center for Research Resources (NCRR) (1)
Studies
Open first, then newest update. How each study uses sevirumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)CompletedPhase 2/3Johns Hopkins Bloomberg School of Public HealthNCT00000135Written as MSL-109
- A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000836Written as Sevirumab
- A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or ViruriaCompletedPhase 1SandozNCT00002268Written as Sevirumab
- A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV RetinitisCompletedPhase 1SandozNCT00002016Written as Sevirumab
- Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System DiseaseCompletedPhase 1/2National Center for Research Resources (NCRR)NCT00004642Written as SDZ MSL-109
Codes
What other systems call sevirumab · ClinicalTrials.gg INT004241
- UNII (FDA) HV6MT68KKFSEVIRUMABOne source FDA
- NCI Thesaurus C188584SevirumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HV6MT68KKF | SEVIRUMAB | One source FDA |
| NCI Thesaurus | C188584 | Sevirumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.